Sepsis kills more than a quarter of a million patients per year in the US alone. Treatments are limited primarily to supportive care. Our project seeks to develop a device to treat sepsis by reprogramming the immune response and redirecting immune effector cells to the nidus of infection and away from healthy tissue.

Treatment with an immune modulating device restores cytokine
gradients between infected tissue and systemic circulation.
Leukocytes are redirected toward the infection
and away from healthy tissue.